Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

导出 OA

翻译打印收藏纠错

作者： Jason P,Lynch ^[1] ; Lisa,Goers ^[1] ; Cammie F,Lesser ^[2]

作者单位： Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. ^[1] Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: clesser@mgh.harvard.edu. ^[2]

关键词 Escherichia coli Nissle 1917 bioengineering colibactin microbial therapeutics synthetic biology

主题词动物(Animals);大肠杆菌(Escherichia coli);人类(Humans);炎性肠疾病(Inflammatory Bowel Diseases);哺乳动物(Mammals);有益菌种(Probiotics)

DOI 10.1016/j.tips.2022.02.002

PMID 35232591

发布时间 2024-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交